Dávid Bárdos, Helga Szakadáti, Lóránd Váncza, Bálint Drácz, Katalin Dezső, Kornélia Baghy, Attila Szijártó, Ilona Kovalszky, Klára Werling
{"title":"[The role of the SPOCK1 protein in healthy and pathological liver processes].","authors":"Dávid Bárdos, Helga Szakadáti, Lóránd Váncza, Bálint Drácz, Katalin Dezső, Kornélia Baghy, Attila Szijártó, Ilona Kovalszky, Klára Werling","doi":"10.1556/650.2025.33206","DOIUrl":null,"url":null,"abstract":"<p><p>Diseases of the liver pose a significant global health challenge, often being diagnosed late and difficult to treat. Therefore, understanding the pathological processes of the liver and identifying new biomarkers and therapeutic targets are of paramount importance, as these efforts may contribute to early diagnosis, more effective treatment strategies, and better patient outcomes. The SPARC/Osteonectin CWCV and Kazal-like domains proteoglycan 1 (SPOCK1) protein, first described in 1992, may play a crucial role in healthy and pathological liver processes, particularly in liver cancer and liver fibrosis. SPOCK1 is a multi-domain protein located both in the extracellular matrix and intracellularly, especially near the mitochondria. It is present in small amounts in a healthy liver, but its expression increases significantly in pathological conditions, such as HCV infection, cirrhosis, and liver cancer. SPOCK1 promotes cell growth, migration, and invasion, while inhibiting apoptosis, thus contributing to tumor and fibrosis progression through the activation of multiple signaling pathways. SPOCK1 represents a potential biomarker and therapeutic target for liver cancer and other liver diseases. However, further research is needed to understand its clinical applications and significance, particularly regarding its functions and secretion mechanisms. Orv Hetil. 2025; 165(3): 82–89.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 3","pages":"82-89"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orvosi hetilap","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1556/650.2025.33206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Diseases of the liver pose a significant global health challenge, often being diagnosed late and difficult to treat. Therefore, understanding the pathological processes of the liver and identifying new biomarkers and therapeutic targets are of paramount importance, as these efforts may contribute to early diagnosis, more effective treatment strategies, and better patient outcomes. The SPARC/Osteonectin CWCV and Kazal-like domains proteoglycan 1 (SPOCK1) protein, first described in 1992, may play a crucial role in healthy and pathological liver processes, particularly in liver cancer and liver fibrosis. SPOCK1 is a multi-domain protein located both in the extracellular matrix and intracellularly, especially near the mitochondria. It is present in small amounts in a healthy liver, but its expression increases significantly in pathological conditions, such as HCV infection, cirrhosis, and liver cancer. SPOCK1 promotes cell growth, migration, and invasion, while inhibiting apoptosis, thus contributing to tumor and fibrosis progression through the activation of multiple signaling pathways. SPOCK1 represents a potential biomarker and therapeutic target for liver cancer and other liver diseases. However, further research is needed to understand its clinical applications and significance, particularly regarding its functions and secretion mechanisms. Orv Hetil. 2025; 165(3): 82–89.
期刊介绍:
The journal publishes original and review papers in the fields of experimental and clinical medicine. It covers epidemiology, diagnostics, therapy and the prevention of human diseases as well as papers of medical history.
Orvosi Hetilap is the oldest, still in-print, Hungarian publication and also the one-and-only weekly published scientific journal in Hungary.
The strategy of the journal is based on the Curatorium of the Lajos Markusovszky Foundation and on the National and International Editorial Board. The 150 year-old journal is part of the Hungarian Cultural Heritage.